Phase II Study of BI 2536 in Prostate Cancer

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00706498
First received: June 24, 2008
Last updated: April 30, 2014
Last verified: April 2014

June 24, 2008
April 30, 2014
September 2006
February 2008   (final data collection date for primary outcome measure)
PSA response rate at 12 weeks according to Prostate Specific Antigen Working Group (PSAWG) criteria. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
PSA response rate at 12 weeks according to Prostate Specific Antigen Working Group (PSAWG) criteria. [ Time Frame: 12 weeks ]
Complete list of historical versions of study NCT00706498 on ClinicalTrials.gov Archive Site
  • PSA response duration [ Time Frame: at least 12 weeks ] [ Designated as safety issue: No ]
  • Time to PSA progression assessed at 24 weeks [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Overall objective response using RECIST criteria (complete response [CR] or partial response [PR]) in patients with measurable disease [ Time Frame: at least 12 weeks ] [ Designated as safety issue: No ]
  • Time to death [ Time Frame: at least 12 weeks ] [ Designated as safety issue: No ]
  • Time to overall progression [ Time Frame: at least 12 weeks ] [ Designated as safety issue: No ]
  • Progression free survival [ Time Frame: at least 12 weeks ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: at least 12 weeks ] [ Designated as safety issue: No ]
  • Duration of overall response (RECIST) [ Time Frame: at least 12 weeks ] [ Designated as safety issue: No ]
  • BI 2536 plasma concentrations [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Incidence and intensity of AEs, with grading according to the US National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Number of patients with changes in laboratory safety parameters [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
PSA progression PSA response duration after 12 weeks Time to PSA progression after 24 weeks Overall objective response and duration Progression free survival and overall survival Pharmacokinetics Time to Overall Progression or Death [ Time Frame: 1 year ]
Not Provided
Not Provided
 
Phase II Study of BI 2536 in Prostate Cancer
A Single Arm Phase II Study to Investigate the Efficacy, Safety and Pharmacokinetics of a Single Dose of 200 mg of i.v. BI 2536, Administered Once Every 3 Weeks in Patients With Advanced Metastatic Hormone-refractory Prostate Cancer.

A study to investigate the activity of BI 2536 in Prostate Cancer

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Prostatic Neoplasms
Drug: BI 2536
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
Not Provided
February 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male patient age >18 years.
  • Signed informed consent.
  • Able to comply with protocol requirements.
  • Patients with histologically, cytologically or biochemically documented metastatic adenocarcinoma of the prostate, clinically refractory or resistant to hormone therapy, as documented by progression following at least one hormonal therapy, which must include orchidectomy or gonadotropin releasing hormone agonist (GnRHa).
  • Patients with Progressive Disease (PD). PD is defined as a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which document progressively increasing PSA values. Patients with progression of measurable disease (RECIST) or progression of bone disease must also fit the criterion for PSA progression.
  • Patients must have documented progression (as defined above) following anti-androgen withdrawal of 4 weeks duration for flutamide and 6 weeks for bicalutamide or nilutamide. For a patient who has withdrawn from anti-androgen therapy less than 6 months prior to inclusion in the trial, one of the following criteria is also required:
  • Following completion of the anti-androgen withdrawal period one PSA measurement should be higher than the last pre-withdrawal PSA.

Or

  • Following the completion of the anti-androgen withdrawal period if the PSA value has decreased, a patient can still qualify if 2 increases in PSA are documented after the post- withdrawal nadir.
  • PSA > 10 ng/ml.
  • A predicted life expectancy of at least 12 weeks.
  • A maximum of one prior treatment with either chemotherapy or other non-hormonal treatment modality.
  • ECOG performance status 0-1.
  • Stable analgesia requirements.
  • INR Prothrombin time (PT) and partial thromboplastin time (PTT) <1.5 upper limit of normal.
  • Adequate bone marrow function defined as absolute neutrophil count (ANC) > 1.5 x 109l, Platelet count > 100 x 109/l.
  • Haemoglobin > 9.0 mg/dl.
  • Serum Albumin > 2.0 g/l.
  • Castrate testosterone level [< 20 ng/dl or <0.69nM (nM/L x 28.8 = ng/dl)] must be maintained during the duration of the trial by orchidectomy or medical castration.
  • Patients on oral or intravenous bisphosphonates are allowed to enter the trial as long as they have been on bisphosphonates for a minimum of 3 months.

Exclusion Criteria:

  • Prior treatment with more than one cytotoxic chemotherapy regimen.
  • Known or suspected hypersensitivity to the trial drug or their excipients.
  • Persistence of toxicities of prior anti-cancer therapies which are deemed to be clinically relevant.
  • Aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 2.5 times the upper limit of normal, or aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 5 times the upper limit of normal in case of known liver metastases.
  • Bilirubin greater than 1.5 mg/dl (> 26 micromol/l, Si unit equivalent). Serum creatinine greater than 2.0 g/l.
  • Concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug.
  • Systemic corticosteroids taken within the past 28 days before screening (inhaled corticosteroids prescribed for bronchospasm are allowed). Patients on long-term stable-dose steroids for concurrent illness are not excluded.
  • Treatment with any investigational drug within 28 days of trial onset.
  • History of other malignancies which could affect compliance with the protocol or interpretation of results within 5-years. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
  • Patient with history or clinical evidence of CNS disease or brain metastases.
  • Patients with symptoms of impending or established spinal cord compression.
  • Radiotherapy within the past four weeks prior to treatment with the trial drug.
  • Prior radioisotope therapy (except radium-223 which is permissible).
  • Immunotherapy within the past four weeks prior to treatment with the trial drug.
  • Patients unable to comply with the protocol.
  • Active alcohol or drug abuse.
  • Patients who do not use adequate contraception.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00706498
1216.19
Not Provided
Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP